| 5.42 0.38 (7.54%) | 05-15 10:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.63 |
1-year : | 7.74 |
| Resists | First : | 5.68 |
Second : | 6.63 |
| Pivot price | 4.38 |
|||
| Supports | First : | 3.94 |
Second : | 2.88 |
| MAs | MA(5) : | 5.16 |
MA(20) : | 4.21 |
| MA(100) : | 3.4 |
MA(250) : | 3.57 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 84.5 |
D(3) : | 82.1 |
| RSI | RSI(14): 76.7 |
|||
| 52-week | High : | 6.26 | Low : | 0.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LIXT ] has closed below upper band by 12.3%. Bollinger Bands are 214.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.33 - 5.36 | 5.36 - 5.39 |
| Low: | 4.68 - 4.72 | 4.72 - 4.75 |
| Close: | 4.98 - 5.04 | 5.04 - 5.09 |
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Thu, 14 May 2026
LIXTE Biotechnology Holdings, Inc. Files Q1 2026 10-Q Report, Highlights Progress in Cancer Treatment Development - Quiver Quantitative
Thu, 14 May 2026
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update - GlobeNewswire
Thu, 14 May 2026
Inside LIXTE’s push on ovarian cancer and proton therapy - Stock Titan
Thu, 14 May 2026
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 1Q 2026: Net loss $1.94M, EPS $(0.18) — 10-Q Summary - TradingView
Thu, 14 May 2026
Lixte (NASDAQ: LIXT) Q1 2026 loss deepens amid going-concern risks - Stock Titan
Mon, 27 Apr 2026
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 4.7 (%) |
| Held by Institutions | 7.4 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 56 (K) |
| EPS | -1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46 % |
| Return on Equity (ttm) | -102 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -4.41 |
| PEG Ratio | 0 |
| Price to Book value | 6.16 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|